Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1989 Sep;84(3):971–975. doi: 10.1172/JCI114260

Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies.

C L Schumacher 1, B Dietzschold 1, H C Ertl 1, H S Niu 1, C E Rupprecht 1, H Koprowski 1
PMCID: PMC329743  PMID: 2760222

Abstract

Immunization of mice and hamsters with a cocktail of mouse MAbs specific for rabies virus nucleocapsid protein and glycoprotein protected animals not only when challenged with a lethal dose of rabies virus after immunization, but also in post-exposure situations. Hamsters treated with the MAb cocktail 3 h after virus inoculation were completely protected from lethal rabies virus infection, and 80% of the animals survived when the MAb cocktail was given 36 h after virus challenge. The potential usefulness of this MAb cocktail for the postexposure treatment of human rabies is discussed.

Full text

PDF
971

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Celis E., Wiktor T. J., Dietzschold B., Koprowski H. Amplification of rabies virus-induced stimulation of human T-cell lines and clones by antigen-specific antibodies. J Virol. 1985 Nov;56(2):426–433. doi: 10.1128/jvi.56.2.426-433.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chang T. W., Testa D., Kung P. C., Perry L., Dreskin H. J., Goldstein G. Cellular origin and interactions involved in gamma-interferon production induced by OKt3 monoclonal antibody. J Immunol. 1982 Feb;128(2):585–589. [PubMed] [Google Scholar]
  3. Davies D. R., Metzger H. Structural basis of antibody function. Annu Rev Immunol. 1983;1:87–117. doi: 10.1146/annurev.iy.01.040183.000511. [DOI] [PubMed] [Google Scholar]
  4. Foon K. A., Schroff R. W., Bunn P. A., Mayer D., Abrams P. G., Fer M., Ochs J., Bottino G. C., Sherwin S. A., Carlo D. J. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood. 1984 Nov;64(5):1085–1093. [PubMed] [Google Scholar]
  5. Habel K. Laboratory techniques in rabies. Habel test for potency. Monogr Ser World Health Organ. 1966;23:140–143. [PubMed] [Google Scholar]
  6. Hughes E. N., August J. T. Murine cell surface glycoproteins. Identification, purification, and characterization of a major glycosylated component of 110,000 daltons by use of a monoclonal antibody. J Biol Chem. 1982 Apr 10;257(7):3970–3977. [PubMed] [Google Scholar]
  7. KOPROWSKI H., VAN DER SCHEER J., BLACK J. Use of hyperimmune anti-rabies serum concentrates in experimental rabies. Am J Med. 1950 Apr;8(4):412–420. doi: 10.1016/0002-9343(50)90224-5. [DOI] [PubMed] [Google Scholar]
  8. Sears H. F., Atkinson B., Mattis J., Ernst C., Herlyn D., Steplewski Z., Häyry P., Koprowski H. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet. 1982 Apr 3;1(8275):762–765. doi: 10.1016/s0140-6736(82)91811-6. [DOI] [PubMed] [Google Scholar]
  9. Sears H. F., Herlyn D., Steplewski Z., Koprowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod. 1984;3(2):138–150. [PubMed] [Google Scholar]
  10. Sears H. F., Herlyn D., Steplewski Z., Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 1985 Nov;45(11 Pt 2):5910–5913. [PubMed] [Google Scholar]
  11. Sikes R. K., Cleary W. F., Koprowski H., Wiktor T. J., Kaplan M. M. Effective protection of monkeys against death from street virus by post-exposure administration of tissue-culture rabies vaccine. Bull World Health Organ. 1971;45(1):1–11. [PMC free article] [PubMed] [Google Scholar]
  12. Turner G. S. Immunoglobulin (IgG) and (IgM) antibody responses to rabies vaccine. J Gen Virol. 1978 Sep;40(3):595–604. doi: 10.1099/0022-1317-40-3-595. [DOI] [PubMed] [Google Scholar]
  13. Wiktor T. J., Dietzschold B., Leamnson R. N., Koprowski H. Induction and biological properties of defective interfering particles of rabies virus. J Virol. 1977 Feb;21(2):626–635. doi: 10.1128/jvi.21.2.626-635.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wiktor T. J., Koprowski H. Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3938–3942. doi: 10.1073/pnas.75.8.3938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wiktor T. J., Macfarlan R. I., Foggin C. M., Koprowski H. Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand. 1984;57:199–211. [PubMed] [Google Scholar]
  16. Wilde H., Chomchey P., Prakongsri S., Puyaratabandhu P., Chutivongse S. Adverse effects of equine rabies immune gobulin. Vaccine. 1989 Feb;7(1):10–11. doi: 10.1016/0264-410x(89)90003-0. [DOI] [PubMed] [Google Scholar]
  17. Wilde H., Choomkasien P., Hemachudha T., Supich C., Chutivongse S. Failure of rabies postexposure treatment in Thailand. Vaccine. 1989 Feb;7(1):49–52. doi: 10.1016/0264-410x(89)90010-8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES